<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03457727</url>
  </required_header>
  <id_info>
    <org_study_id>207573</org_study_id>
    <nct_id>NCT03457727</nct_id>
  </id_info>
  <brief_title>GSK1325756 Relative Bioavailability Study in Healthy Elderly Subjects</brief_title>
  <official_title>A Two Part, Randomized, Open-label, Cross Over Study in Healthy Elderly Participants to Evaluate the Relative Bioavailability of Hydrobromide Salt Tablet Formulations of Danirixin in the Fed and Fasted States, and to Evaluate the Effect of Food and Gastric Acid Secretion Suppression on Danirixin Pharmacokinetics Following Administration of Hydrobromide Salt Tablets</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This 2-part study will be carried out on healthy elderly subjects to evaluate relative
      bioavailability of danirixin formulations. Part A will support the selection of the
      formulation and Part B will assess food effect, bioavailability and pharmacokinetic (PK)
      profile of selected formulation from Part A. Danirixin is currently administered with food,
      therefore the investigation of food effect for the selected formulation could potentially
      enable dosing without food. Approximately 16 subjects will be included in Part A and
      approximately 24 subjects will be included in Part B. Both parts will include a screening
      phase, treatment phase with in-between washout period and a follow-up phase.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 7, 2018</start_date>
  <completion_date type="Actual">July 25, 2018</completion_date>
  <primary_completion_date type="Actual">July 25, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Subjects will receive danirixin reference and test formulations in a cross-over manner.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>This will be an open-label study and blinding will not be performed.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Area Under the Concentration-time Curve From Time 0 to Infinity (AUC [0-inf]) of Danirixin for Part 1</measure>
    <time_frame>Pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48 hours in Part 1</time_frame>
    <description>Blood samples were collected at the indicated time points after administration of study treatment to investigate the pharmacokinetic (PK) profile of Danirixin. PK parameters were calculated by standard non-compartmental analysis using WinNonlin based on actual sampling times.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Observed Concentration (Cmax) of Danirixin for Part 1</measure>
    <time_frame>Pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48 hours in Part 1</time_frame>
    <description>Blood samples were collected at the indicated time points after administration of study treatment to investigate the PK profile of Danirixin. PK parameters were calculated by standard non-compartmental analysis using WinNonlin based on actual sampling times.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Any Adverse Event (AE) and Serious Adverse Events (SAEs) in Part 1</measure>
    <time_frame>Up to 29 days in Part 1</time_frame>
    <description>AE is any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. An SAE is any untoward medical occurrence that, at any dose results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect or is medically significant.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Vital Signs of Potential Clinical Concern in Part 1</measure>
    <time_frame>Up to 29 days in Part 1</time_frame>
    <description>Vital signs included systolic and diastolic blood pressure, temperature, respiratory rate and pulse rate were measured with participants in semi-supine position after 5 minutes rest.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With 12-lead Electrocardiogram (ECG) Values of Potential Clinical Concern in Part 1</measure>
    <time_frame>Up to 29 days in Part 1</time_frame>
    <description>Single 12-lead ECGs were obtained using an ECG machine that automatically calculated the heart rate and measured PR, QRS, and QT intervals, and QT interval corrected by Fridericia's formula (QTcF). Number of participants with 12-lead ECG values of potential clinical concern in Part 1 are presented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Laboratory Values of Potential Clinical Concern in Part 1</measure>
    <time_frame>Up to 29 days in Part 1</time_frame>
    <description>Hematology parameters included platelet count, RBC Count, hemoglobin, hematocrit, MCV, MCH, %Reticulocytes, neutrophils, lymphocytes, monocytes, eosinophils, basophils. Clinical chemistry parameters included potassium aspartate aminotransferase(AST)/Serum Glutamic-Oxaloacetic Transaminase (SGOT), total and direct bilirubin, creatinine, sodium alanine, aminotransferase, (ALT)/ Serum Glutamic-Pyruvic, Transaminase (SGPT), total protein, fasting glucose, calcium, alkaline phosphatase and albumin. Urinalysis included specific gravity, potential of hydrogen (pH), glucose, protein, blood and ketones by dipstick and microscopic examination of urine.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area Under the Concentration-time Curve From Time 0 to t (AUC [0-t]) of Danirixin for Part 1</measure>
    <time_frame>Pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48 hours in Part 1</time_frame>
    <description>Blood samples were collected at the indicated time points after administration of study treatment to investigate the PK profile of Danirixin. PK parameters were calculated by standard non-compartmental analysis using WinNonlin based on actual sampling times.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Concentration-time Curve From Time 0 to 24 Hours Post-dose (AUC [0-24]) of Danirixin for Part 1</measure>
    <time_frame>Pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48 hours in Part 1</time_frame>
    <description>Blood samples were collected at the indicated time points after administration of study treatment to investigate the PK profile of Danirixin. PK parameters were calculated by standard non-compartmental analysis using WinNonlin based on actual sampling times.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Occurrence of Cmax (Tmax) of Danirixin for Part 1</measure>
    <time_frame>Pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48 hours in Part 1</time_frame>
    <description>Blood samples were collected at the indicated time points after administration of study treatment to investigate the PK profile of Danirixin. PK parameters were calculated by standard non-compartmental analysis using WinNonlin based on actual sampling times.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal Half-life (t1/2) of Danirixin for Part 1</measure>
    <time_frame>Pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48 hours in Part 1</time_frame>
    <description>Blood samples were collected at the indicated time points after administration of study treatment to investigate the PK profile of Danirixin. PK parameters were calculated by standard non-compartmental analysis using WinNonlin based on actual sampling times.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Last Quantifiable Concentration (Tlast) of the Blood Concentration of Danirixin for Part 1</measure>
    <time_frame>Pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48 hours in Part 1</time_frame>
    <description>Blood samples were collected at the indicated time points after administration of study treatment to investigate the PK profile of Danirixin. PK parameters were calculated by standard non-compartmental analysis using WinNonlin based on actual sampling times.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lag Time Before Observation of Drug Concentrations in Sampled Matrix (Tlag) of Danirixin for Part 1</measure>
    <time_frame>Pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48 hours in Part 1</time_frame>
    <description>Blood samples were collected at the indicated time points after administration of study treatment to investigate the PK profile of Danirixin. PK parameters were calculated by standard non-compartmental analysis using WinNonlin based on actual sampling times.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Concentration-time Curve From Time 0 to Infinity (AUC [0-inf]) of Danirixin for Part 2</measure>
    <time_frame>Pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48 hours in Part 2</time_frame>
    <description>Blood samples were collected at the indicated time points after administration of study treatment to investigate the PK profile of Danirixin. PK parameters were calculated by standard non-compartmental analysis using WinNonlin based on actual sampling times.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Concentration-time Curve From Time 0 to t (AUC [0-t]) of Danirixin for Part 2</measure>
    <time_frame>Pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48 hours in Part 2</time_frame>
    <description>Blood samples were collected at the indicated time points after administration of study treatment to investigate the PK profile of Danirixin. PK parameters were calculated by standard non-compartmental analysis using WinNonlin based on actual sampling times.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Concentration-time Curve From Time 0 to 24 Hours (AUC [0-24]) of Danirixin for Part 2</measure>
    <time_frame>Pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48 hours in Part 2</time_frame>
    <description>Blood samples were collected at the indicated time points after administration of study treatment to investigate the PK profile of Danirixin. PK parameters were calculated by standard non-compartmental analysis using WinNonlin based on actual sampling times.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Concentration (Cmax) of Danirixin for Part 2</measure>
    <time_frame>Pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48 hours in Part 2</time_frame>
    <description>Blood samples were collected at the indicated time points after administration of study treatment to investigate the PK profile of Danirixin. PK parameters were calculated by standard non-compartmental analysis using WinNonlin based on actual sampling times.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Maximum Observed Concentration (Tmax) of Danirixin for Part 2</measure>
    <time_frame>Pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48 hours in Part 2</time_frame>
    <description>Blood samples were collected at the indicated time points after administration of study treatment to investigate the PK profile of Danirixin. PK parameters were calculated by standard non-compartmental analysis using WinNonlin based on actual sampling times.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal Half-life (t1/2) of Danirixin for Part 2</measure>
    <time_frame>Pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48 hours in Part 2</time_frame>
    <description>Blood samples were collected at the indicated time points after administration of study treatment to investigate the PK profile of Danirixin. PK parameters were calculated by standard non-compartmental analysis using WinNonlin based on actual sampling times.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Last Quantifiable Concentration (Tlast) of the Blood Concentration of Danirixin for Part 2</measure>
    <time_frame>Pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48 hours in Part 2</time_frame>
    <description>Blood samples were collected at the indicated time points after administration of study treatment to investigate the PK profile of Danirixin. PK parameters were calculated by standard non-compartmental analysis using WinNonlin based on actual sampling times.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lag Time Before Observable Concentration (Tlag) of Danirixin for Part 2</measure>
    <time_frame>Pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48 hours in Part 2</time_frame>
    <description>Blood samples were collected at the indicated time points after administration of study treatment to investigate the PK profile of Danirixin. PK parameters were calculated by standard non-compartmental analysis using WinNonlin based on actual sampling times.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Any Adverse Event (AE) and Serious Adverse Events in Part 2</measure>
    <time_frame>Up to 52 days in Part 2</time_frame>
    <description>AE is any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. An SAE is any untoward medical occurrence that, at any dose results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect or is medically significant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Vital Signs of Potential Clinical Concern in Part 2</measure>
    <time_frame>Up to 52 days in Part 2</time_frame>
    <description>Vital signs included systolic and diastolic blood pressure, temperature, respiratory rate and pulse rate were measured with participants in semi-supine position after 5 minutes rest.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With 12-lead Electrocardiogram (ECG) Values of Potential Clinical Concern in Part 2</measure>
    <time_frame>Up to 52 days in Part 2</time_frame>
    <description>Single 12-lead ECGs were obtained using an ECG machine that automatically calculated the heart rate and measured PR, QRS, and QT intervals, and QT interval corrected by Fridericia's formula (QTcF). Number of participants with 12-lead ECG values of potential clinical concern in Part 2 are presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Laboratory Values of Potential Clinical Concern in Part 2</measure>
    <time_frame>Up to 52 days in Part 2</time_frame>
    <description>Hematology parameters included platelet count, RBC Count, hemoglobin, hematocrit, MCV, MCH, %Reticulocytes, neutrophils, lymphocytes, monocytes, eosinophils, basophils. Clinical chemistry parameters included potassium aspartate, Aminotransferase(AST)/Serum Glutamic-Oxaloacetic Transaminase (SGOT), total and direct, bilirubin, creatinine sodium alanine, Aminotransferase, (ALT)/ Serum Glutamic-Pyruvic, Transaminase (SGPT), total protein, fasting glucose, calcium, alkaline phosphatase and albumin. Urinalysis included specific gravity, potential of hydrogen (pH), glucose, protein, blood and ketones by dipstick and microscopic examination of urine.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Pulmonary Disease, Chronic Obstructive</condition>
  <arm_group>
    <arm_group_label>Subjects receiving danirixin: Part A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive a single oral dose of 50 mg danirixin reference and test formulations with food and 240 mL of water in a cross-over manner.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Subjects receiving danirixin without omeprazole: Part B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive a single oral dose of 50 mg danirixin formulation (selected in Part A) in fasted or fed state in a cross-over manner.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Subjects receiving danirixin with omeprazole: Part B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive a single oral dose of 50 mg danirixin formulation (selected in Part A) along with once daily 40 mg OMP capsule in fasted or fed state in a cross-over manner.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Danirixin</intervention_name>
    <description>Danirixin is being developed as a potential anti-inflammatory agent for the treatment of chronic obstructive pulmonary disorder (COPD) and other inflammatory diseases and influenza. Danirixin reference (600 mg) or test formulation (475 or 600 mg or 600 mg with 5 percent HPMC) immediate release tablets will be administered by oral route in a cross-over manner.</description>
    <arm_group_label>Subjects receiving danirixin with omeprazole: Part B</arm_group_label>
    <arm_group_label>Subjects receiving danirixin without omeprazole: Part B</arm_group_label>
    <arm_group_label>Subjects receiving danirixin: Part A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Omeprazole</intervention_name>
    <description>Omeprazole is used as an antacid. OMP 40 mg delayed-release capsule will be administered by oral route to randomized subjects.</description>
    <arm_group_label>Subjects receiving danirixin with omeprazole: Part B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects must be 65 to 80 years of age inclusive, at the Screening Visit.

          -  Subjects who are healthy, as determined by a responsible and experienced physician,
             based on a medical evaluation including medical history, physical examination,
             laboratory tests and cardiac monitoring or a subject with a clinical abnormality or
             laboratory parameters outside the reference range for the population being studied may
             be included if the investigator and the GlaxoSmithKline (GSK) Medical Monitor agree
             that the finding is unlikely to introduce risk factors and will not interfere with the
             study procedures and objectives. Additionally, laboratory assessments that are
             specifically listed in the inclusion or exclusion criteria and are outside of the
             reference range can be repeated once during the screening period.

          -  Body weight &gt;=50 kilograms (kg) and body mass index (BMI) within the range 19 - 34 kg
             per meter square (kg/m^2) (inclusive).

          -  Male or female subjects will be included. A female subject is eligible to participate
             if she is not pregnant, not breastfeeding, and at least one of the following
             conditions applies: Not a woman of childbearing potential (WOCBP) or a WOCBP who
             agrees to follow the contraceptive guidance during the treatment period and for at
             least 60 hours after the last dose of study treatment.

          -  Capable of giving signed informed consent.

          -  AST, ALT, alkaline phosphatase and bilirubin &lt;= 1.5 × upper limit of normal (ULN)
             (isolated bilirubin &gt; 1.5 × ULN is acceptable if bilirubin is fractionated and direct
             bilirubin &lt; 35 percent).

          -  Resting BP of &lt;= 160/90 millimeters of mercury (mmHg), irrespective of
             anti-hypertensive medication status for the subject.

          -  Able to consume the Food and Drug Administration (FDA) defined high fat meal within 30
             minutes in each of the four treatment periods where study treatment is administered in
             a fed state.

        Exclusion Criteria:

          -  Significant history of or current cardiovascular, respiratory, hepatic, renal,
             gastrointestinal, endocrine, hematological, or neurological disorders capable of
             significantly altering the absorption, metabolism, or elimination of drugs;
             constituting a risk when taking the study treatment; or interfering with the
             interpretation of data.

          -  Evidence of active or latent tuberculosis (TB) as documented by medical history and
             examination, chest x-rays (posterior anterior and lateral), and TB testing: either a
             positive tuberculin skin test [TST; defined as a skin induration &lt;5 millimeter (mm) at
             48 to 72 hours, regardless of Bacillus Calmette-Guerin (BCG) or other vaccination
             history] or a positive (not indeterminate) QuantiFERON®-TB Gold test.

          -  Lymphoma, leukemia, or any malignancy within the past 5 years except for basal cell or
             squamous epithelial carcinomas of the skin that have been resected with no evidence of
             metastatic disease for 3 years.

          -  Breast cancer within the past 10 years.

          -  ALT &gt;1.5x ULN

          -  Bilirubin &gt;1.5xULN (isolated bilirubin &gt;1.5xULN is acceptable if bilirubin is
             fractionated and direct bilirubin &lt;35 percent).

          -  Current or chronic history of liver disease, or known hepatic or biliary abnormalities
             (with the exception of Gilbert's syndrome or asymptomatic gallstones).

          -  Corrected QT interval (QTc) &gt;450 milliseconds (msec).

          -  Use of prescription or non-prescription drugs, including proton pump inhibitors,
             histamine receptor 2 antagonists, systemic antacid medications (unless these can be
             held during the study), vitamins, herbal and dietary supplements (including St John's
             Wort) within 7 days (or 14 days if the drug is a potential enzyme inducer) or 5
             half-lives (whichever is longer) prior to the first dose of study treatment until
             completion of the last study assessment , unless in the opinion of the investigator
             and GSK Medical Monitor, the medication will not interfere with the study procedures
             or compromise subject safety. Some examples of exceptions (permitted medications) are:
             Stable dose of anti-hypertensive medication for at least 3 months prior to the
             screening visit; Stable dose of lipid-lowering medications (statins or fibrates) for
             at least 3 months prior to the screening visit; Antacids up to 24 hours prior to
             dosing.

          -  Participation in the study would result in loss of blood or blood products in excess
             of 500 milliliter (mL) within 3 months.

          -  The subject has participated in a clinical trial and has received an investigational
             product within the following time period prior to the first dosing day in the current
             study: 3 months, 5 half-lives or twice the duration of the biological effect of the
             investigational product (whichever is longer).

          -  Exposure to more than 4 new chemical entities within 12 months prior to the first
             dosing day.

          -  Participation in a previous clinical trial with danirixin within 1 year prior to the
             first dosing day in the current study.

          -  Female Subjects: Positive urine beta-human chorionic gonadotropin (beta-hCG) test at
             screening.

          -  Presence of Hepatitis B surface antigen (HBsAg) at screening Positive Hepatitis C
             antibody test result at screening.

          -  Positive Hepatitis C ribonucleic acid (RNA) test result at screening or within 3
             months prior to first dose of study treatment.

          -  For potent immunosuppressive agents, presence of the Hepatitis B core antibody (HBcAb)
             should also lead to exclusion from the study even if HBsAg is negative.

          -  Positive pre-study drug/alcohol screen.

          -  Positive human immunodeficiency virus (HIV) antibody test.

          -  Regular use of known drugs of abuse.

          -  Regular alcohol consumption within 6 months prior to the study defined as: an average
             weekly intake of &gt;21 units for males or &gt;14 units for females. One unit is equivalent
             to 8 grams of alcohol: a half-pint (approximately 240 mL) of beer, 1 glass (125 mL) of
             wine or 1 (25 mL) measure of spirits.

          -  Consumption of red wine, Seville oranges, grapefruit or grapefruit juice and/or
             pummelos, citrus fruits, grapefruit hybrids or fruit juices from 7 days prior to the
             first dose of study treatment until collection of the final blood sample.

          -  Urinary cotinine levels indicative of smoking or history or regular use of tobacco- or
             nicotine-containing products within 90 days prior to screening.

          -  Sensitivity to heparin or heparin-induced thrombocytopenia.

          -  Sensitivity to any of the study treatments, or components thereof, or drug or other
             allergy that, in the opinion of the investigator or medical monitor, contraindicates
             participation in the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>March 1, 2018</study_first_submitted>
  <study_first_submitted_qc>March 1, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 7, 2018</study_first_posted>
  <results_first_submitted>July 16, 2019</results_first_submitted>
  <results_first_submitted_qc>July 16, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">August 28, 2019</results_first_posted>
  <last_update_submitted>July 16, 2019</last_update_submitted>
  <last_update_submitted_qc>July 16, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 28, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Danirixin</keyword>
  <keyword>Healthy</keyword>
  <keyword>Food effect</keyword>
  <keyword>Relative Bioavailability</keyword>
  <keyword>Hydrobromide Salt</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Omeprazole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>IPD for this study will be made available via the Clinical Study Data Request site.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>IPD will be made available within 6 months of publishing the results of the primary endpoints of the study.</ipd_time_frame>
    <ipd_access_criteria>Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.</ipd_access_criteria>
    <ipd_url>http://clinicalstudydatarequest.com</ipd_url>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 6, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/27/NCT03457727/SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>February 22, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/27/NCT03457727/Prot_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This two-part study assessed the relative bioavailability of Danirixin (DNX) tablet formulations along with effect of food and gastric acid secretion suppression on DNX pharmacokinetics. This study was conducted at a single center in the United States from 07-Mar-2018 to 25-Jul-2018.</recruitment_details>
      <pre_assignment_details>Danirixin hemihydrate salt tablet formulation manufactured using roller compaction (RC) was compared to test formulations manufactured by direct compression (DC) with an excipient hydroxypropyl methylcellulose (HPMC) to evaluate the most appropriate formulation/dosing regimen. A total of 40 participants were enrolled in the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>DNX 50 mg 600RC/475DC/600DC/600DC-5% HPMC in Fed State</title>
          <description>Participants received a sequence of the following: single oral dose of 50 milligrams (mg) DNX hydrobromide (HBr) hemihydrate tablet formulation (600 mg tablet manufactured by RC [600 RC]) on Day 1 of treatment period 1, a single oral dose of 50 mg DNX HBr hemihydrate tablet formulation (475 mg tablet manufactured by DC [475 DC]) on Day 1 of treatment period 2, a single oral dose of 50 mg DNX HBr hemihydrate tablet formulation (600 DC) on Day 1 of treatment period 3 and 50 mg DNX HBr hemihydrate 600 DC tablet formulation with containing 5 percent HPMC on Day 1 of treatment period 4. All the formulations were administered in fed state (with a high fat meal). The treatment periods were separated by a washout period of 5 days.</description>
        </group>
        <group group_id="P2">
          <title>DNX 50mg 600RC/475DC/600DC/600DC-5% HPMC in Fasted State</title>
          <description>Participants received a sequence of the following: single oral dose of 50 mg DNX HBr hemihydrate 600 RC on Day 1 of treatment period 1, a single oral dose of 50 mg DNX HBr hemihydrate 475 DC on Day 1 of treatment period 2, a single oral dose 50 mg DNX HBr hemihydrate 600 DC on Day 1 of treatment period 3 and a single oral dose of 50 mg DNX HBr hemihydrate 600 DC with 5 percent HPMC on Day 1 of treatment period 4. All the formulations were administered in fasted state. The treatment periods were separated by a washout period of 5 days.</description>
        </group>
        <group group_id="P3">
          <title>DNX 50 mg 475 DC Under Fasted/Normal/Fat Meal/ Mono-fat Meal</title>
          <description>Participants received a sequence of the following: single oral dose of 50 mg DNX HBr hemihydrate 475 DC tablet formulation in fasted state on Day 1 of treatment period 1, a single oral dose of 50 mg DNX HBr hemihydrate 475 DC along with normal meal on Day 1 of treatment period 2, a single oral dose of 50 mg DNX HBr hemihydrate 475 DC along with high fat meal in treatment period 3, followed by a single oral dose of 50 mg DNX HBr monohydrate 475 DC with high fat meal in treatment period 4. The treatment periods were separated by a washout period of 5 days.</description>
        </group>
        <group group_id="P4">
          <title>DNX 50 mg 475 DC+OMP 40mg Under Fasted/Normal/Fat Meal State</title>
          <description>Participants received a sequence of the following: single oral dose of 50 mg DNX HBr hemihydrate 475 DC in fasted state along with 40 mg omeprazole (OMP) during treatment period 1, a single oral dose of 50 mg DNX HBr hemihydrate 475 DC and 40 mg OMP along with normal meal in treatment period 2 and a single oral dose of 50 mg DNX HBr hemihydrate 475 DC and 40 mg OMP along with high fat meal in treatment period 3. The treatment periods were separated by a washout period of 5 days. OMP was administered from Day -4 of each treatment period through washout periods.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Part 1, Period 1 (1 Day)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Part 1, Washout Period 1 (5 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Part 1, Period 2 (1 Day)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Part 1, Washout Period 2 (5 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Part 1, Period 3 (1 Day)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Part 1, Washout Period 3 (5 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Part 1, Period 4 (1 Day)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Part 2, Period 1 (1 Day)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="12"/>
                <participants group_id="P4" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="12"/>
                <participants group_id="P4" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Part 2, Washout Period 1 (5 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="12"/>
                <participants group_id="P4" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="12"/>
                <participants group_id="P4" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Part 2, Period 2 (1 Day)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="12"/>
                <participants group_id="P4" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="12"/>
                <participants group_id="P4" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Part 2, Washout Period 2 (5 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="12"/>
                <participants group_id="P4" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="12"/>
                <participants group_id="P4" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Part 2, Period 3 (1 Day)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="12"/>
                <participants group_id="P4" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="12"/>
                <participants group_id="P4" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Part 2, Washout Period 3 (5 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="12"/>
                <participants group_id="P4" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="12"/>
                <participants group_id="P4" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Part 2, Period 4 (1 Day)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="12"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="12"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>DNX 50 mg 600RC/475DC/600DC/600DC-5% HPMC in Fed State</title>
          <description>Participants received a sequence of the following: single oral dose of 50 milligrams (mg) DNX hydrobromide (HBr) hemihydrate tablet formulation (600 mg tablet manufactured by RC [600 RC]) on Day 1 of treatment period 1, a single oral dose of 50 mg DNX HBr hemihydrate tablet formulation (475 mg tablet manufactured by DC [475 DC]) on Day 1 of treatment period 2, a single oral dose of 50 mg DNX HBr hemihydrate tablet formulation (600 DC) on Day 1 of treatment period 3 and 50 mg DNX HBr hemihydrate 600 DC tablet formulation with containing 5 percent HPMC on Day 1 of treatment period 4. All the formulations were administered in fed state (with a high fat meal). The treatment periods were separated by a washout period of 5 days.</description>
        </group>
        <group group_id="B2">
          <title>DNX 50mg 600RC/475DC/600DC/600DC-5% HPMC in Fasted State</title>
          <description>Participants received a sequence of the following: single oral dose of 50 mg DNX HBr hemihydrate 600 RC on Day 1 of treatment period 1, a single oral dose of 50 mg DNX HBr hemihydrate 475 DC on Day 1 of treatment period 2, a single oral dose 50 mg DNX HBr hemihydrate 600 DC on Day 1 of treatment period 3 and a single oral dose of 50 mg DNX HBr hemihydrate 600 DC with 5 percent HPMC on Day 1 of treatment period 4. All the formulations were administered in fasted state. The treatment periods were separated by a washout period of 5 days.</description>
        </group>
        <group group_id="B3">
          <title>DNX 50 mg 475 DC Under Fasted/Normal/Fat Meal/ Mono-fat Meal</title>
          <description>Participants received a sequence of the following: single oral dose of 50 mg DNX HBr hemihydrate 475 DC tablet formulation in fasted state on Day 1 of treatment period 1, a single oral dose of 50 mg DNX HBr hemihydrate 475 DC along with normal meal on Day 1 of treatment period 2, a single oral dose of 50 mg DNX HBr hemihydrate 475 DC along with high fat meal in treatment period 3, followed by a single oral dose of 50 mg DNX HBr monohydrate 475 DC with high fat meal in treatment period 4. The treatment periods were separated by a washout period of 5 days.</description>
        </group>
        <group group_id="B4">
          <title>DNX 50 mg 475 DC+OMP 40mg Under Fasted/Normal/Fat Meal State</title>
          <description>Participants received a sequence of the following: single oral dose of 50 mg DNX HBr hemihydrate 475 DC in fasted state along with 40 mg omeprazole (OMP) during treatment period 1, a single oral dose of 50 mg DNX HBr hemihydrate 475 DC and 40 mg OMP along with normal meal in treatment period 2 and a single oral dose of 50 mg DNX HBr hemihydrate 475 DC and 40 mg OMP along with high fat meal in treatment period 3. The treatment periods were separated by a washout period of 5 days. OMP was administered from Day -4 of each treatment period through washout periods.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
            <count group_id="B2" value="8"/>
            <count group_id="B3" value="12"/>
            <count group_id="B4" value="12"/>
            <count group_id="B5" value="40"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="69.4" spread="3.54"/>
                    <measurement group_id="B2" value="70.9" spread="4.58"/>
                    <measurement group_id="B3" value="71.3" spread="4.14"/>
                    <measurement group_id="B4" value="69.4" spread="2.68"/>
                    <measurement group_id="B5" value="70.3" spread="3.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Count of Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Concentration-time Curve From Time 0 to Infinity (AUC [0-inf]) of Danirixin for Part 1</title>
        <description>Blood samples were collected at the indicated time points after administration of study treatment to investigate the pharmacokinetic (PK) profile of Danirixin. PK parameters were calculated by standard non-compartmental analysis using WinNonlin based on actual sampling times.</description>
        <time_frame>Pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48 hours in Part 1</time_frame>
        <population>PK Population includes all participants for whom a PK sample was obtained and analyzed. Only those participants with data available at specified time frame were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>600RC High Fat</title>
            <description>Participants received a single oral dose of DNX 50 mg HBr hemihydrate 600 RC tablet formulation along with a high fat meal</description>
          </group>
          <group group_id="O2">
            <title>475DC High Fat</title>
            <description>Participants received a single oral dose of DNX 50 mg HBr hemihydrate 475 DC tablet formulation along with high fat meal</description>
          </group>
          <group group_id="O3">
            <title>600DC High Fat</title>
            <description>Participants received a single oral dose of DNX 50 mg HBr hemihydrate 600 DC tablet formulation along with high fat meal</description>
          </group>
          <group group_id="O4">
            <title>600DC 5%HPMC High Fat</title>
            <description>Participants received a single oral dose of DNX 50 mg HBr hemihydrate 600 DC tablet with 5 percent HPMC formulation along with high fat meal</description>
          </group>
          <group group_id="O5">
            <title>600RC Fasted</title>
            <description>Participants received a single oral dose of DNX 50 mg HBr hemihydrate 600 RC tablet formulation under fasted condition</description>
          </group>
          <group group_id="O6">
            <title>475DC Fasted</title>
            <description>Participants received a single oral dose of DNX 50 mg HBr hemihydrate 475 DC tablet formulation under fasted condition</description>
          </group>
          <group group_id="O7">
            <title>600DC Fasted</title>
            <description>Participants received a single oral dose of DNX 50 mg HBr hemihydrate 600 DC tablet formulation under fasted condition</description>
          </group>
          <group group_id="O8">
            <title>600DC 5%HPMC Fasted</title>
            <description>Participants received a single oral dose of DNX 50 mg HBr hemihydrate 600 DC tablet with 5 percent HPMC formulation under fasted condition</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Concentration-time Curve From Time 0 to Infinity (AUC [0-inf]) of Danirixin for Part 1</title>
          <description>Blood samples were collected at the indicated time points after administration of study treatment to investigate the pharmacokinetic (PK) profile of Danirixin. PK parameters were calculated by standard non-compartmental analysis using WinNonlin based on actual sampling times.</description>
          <population>PK Population includes all participants for whom a PK sample was obtained and analyzed. Only those participants with data available at specified time frame were analyzed.</population>
          <units>Hours*nanograms per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="7"/>
                <count group_id="O7" value="8"/>
                <count group_id="O8" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6166.7" spread="19.20"/>
                    <measurement group_id="O2" value="6052.9" spread="14.18"/>
                    <measurement group_id="O3" value="5816.4" spread="22.99"/>
                    <measurement group_id="O4" value="5996.1" spread="26.31"/>
                    <measurement group_id="O5" value="11394.6" spread="30.07"/>
                    <measurement group_id="O6" value="11285.7" spread="32.72"/>
                    <measurement group_id="O7" value="10957.4" spread="31.55"/>
                    <measurement group_id="O8" value="11230.8" spread="28.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Maximum Observed Concentration (Cmax) of Danirixin for Part 1</title>
        <description>Blood samples were collected at the indicated time points after administration of study treatment to investigate the PK profile of Danirixin. PK parameters were calculated by standard non-compartmental analysis using WinNonlin based on actual sampling times.</description>
        <time_frame>Pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48 hours in Part 1</time_frame>
        <population>PK population. Only those participants with data available at specified time frame were analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>600RC High Fat</title>
            <description>Participants received a single oral dose of DNX 50 mg HBr hemihydrate 600 RC tablet formulation along with a high fat meal</description>
          </group>
          <group group_id="O2">
            <title>475DC High Fat</title>
            <description>Participants received a single oral dose of DNX 50 mg HBr hemihydrate 475 DC tablet formulation along with high fat meal</description>
          </group>
          <group group_id="O3">
            <title>600DC High Fat</title>
            <description>Participants received a single oral dose of DNX 50 mg HBr hemihydrate 600 DC tablet formulation along with high fat meal</description>
          </group>
          <group group_id="O4">
            <title>600DC 5%HPMC High Fat</title>
            <description>Participants received a single oral dose of DNX 50 mg HBr hemihydrate 600 DC tablet with 5 percent HPMC formulation along with high fat meal</description>
          </group>
          <group group_id="O5">
            <title>600RC Fasted</title>
            <description>Participants received a single oral dose of DNX 50 mg HBr hemihydrate 600 RC tablet formulation under fasted condition</description>
          </group>
          <group group_id="O6">
            <title>475DC Fasted</title>
            <description>Participants received a single oral dose of DNX 50 mg HBr hemihydrate 475 DC tablet formulation under fasted condition</description>
          </group>
          <group group_id="O7">
            <title>600DC Fasted</title>
            <description>Participants received a single oral dose of DNX 50 mg HBr hemihydrate 600 DC tablet formulation under fasted condition</description>
          </group>
          <group group_id="O8">
            <title>600DC 5%HPMC Fasted</title>
            <description>Participants received a single oral dose of DNX 50 mg HBr hemihydrate 600 DC tablet with 5 percent HPMC formulation under fasted condition</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Observed Concentration (Cmax) of Danirixin for Part 1</title>
          <description>Blood samples were collected at the indicated time points after administration of study treatment to investigate the PK profile of Danirixin. PK parameters were calculated by standard non-compartmental analysis using WinNonlin based on actual sampling times.</description>
          <population>PK population. Only those participants with data available at specified time frame were analyzed</population>
          <units>Nanograms/milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="7"/>
                <count group_id="O6" value="8"/>
                <count group_id="O7" value="8"/>
                <count group_id="O8" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="761.5" spread="27.22"/>
                    <measurement group_id="O2" value="712.8" spread="20.53"/>
                    <measurement group_id="O3" value="762.3" spread="37.23"/>
                    <measurement group_id="O4" value="659.2" spread="47.40"/>
                    <measurement group_id="O5" value="2708.2" spread="26.22"/>
                    <measurement group_id="O6" value="2418.5" spread="27.78"/>
                    <measurement group_id="O7" value="2607.1" spread="30.24"/>
                    <measurement group_id="O8" value="2511.8" spread="24.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Any Adverse Event (AE) and Serious Adverse Events (SAEs) in Part 1</title>
        <description>AE is any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. An SAE is any untoward medical occurrence that, at any dose results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect or is medically significant.</description>
        <time_frame>Up to 29 days in Part 1</time_frame>
        <population>Modified Intent-to-treat (mITT) Population includes all randomized participants</population>
        <group_list>
          <group group_id="O1">
            <title>600RC High Fat</title>
            <description>Participants received a single oral dose of DNX 50 mg HBr hemihydrate 600 RC tablet formulation along with a high fat meal</description>
          </group>
          <group group_id="O2">
            <title>475DC High Fat</title>
            <description>Participants received a single oral dose of DNX 50 mg HBr hemihydrate 475 DC tablet formulation along with high fat meal</description>
          </group>
          <group group_id="O3">
            <title>600DC High Fat</title>
            <description>Participants received a single oral dose of DNX 50 mg HBr hemihydrate 600 DC tablet formulation along with high fat meal</description>
          </group>
          <group group_id="O4">
            <title>600DC 5%HPMC High Fat</title>
            <description>Participants received a single oral dose of DNX 50 mg HBr hemihydrate 600 DC tablet with 5 percent HPMC formulation along with high fat meal</description>
          </group>
          <group group_id="O5">
            <title>600RC Fasted</title>
            <description>Participants received a single oral dose of DNX 50 mg HBr hemihydrate 600 RC tablet formulation under fasted condition</description>
          </group>
          <group group_id="O6">
            <title>475DC Fasted</title>
            <description>Participants received a single oral dose of DNX 50 mg HBr hemihydrate 475 DC tablet formulation under fasted condition</description>
          </group>
          <group group_id="O7">
            <title>600DC Fasted</title>
            <description>Participants received a single oral dose of DNX 50 mg HBr hemihydrate 600 DC tablet formulation under fasted condition</description>
          </group>
          <group group_id="O8">
            <title>600DC 5%HPMC Fasted</title>
            <description>Participants received a single oral dose of DNX 50 mg HBr hemihydrate 600 DC tablet with 5 percent HPMC formulation under fasted condition</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Any Adverse Event (AE) and Serious Adverse Events (SAEs) in Part 1</title>
          <description>AE is any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. An SAE is any untoward medical occurrence that, at any dose results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect or is medically significant.</description>
          <population>Modified Intent-to-treat (mITT) Population includes all randomized participants</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="8"/>
                <count group_id="O7" value="8"/>
                <count group_id="O8" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any SAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Vital Signs of Potential Clinical Concern in Part 1</title>
        <description>Vital signs included systolic and diastolic blood pressure, temperature, respiratory rate and pulse rate were measured with participants in semi-supine position after 5 minutes rest.</description>
        <time_frame>Up to 29 days in Part 1</time_frame>
        <population>mITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>600RC High Fat</title>
            <description>Participants received a single oral dose of DNX 50 mg HBr hemihydrate 600 RC tablet formulation along with a high fat meal</description>
          </group>
          <group group_id="O2">
            <title>475DC High Fat</title>
            <description>Participants received a single oral dose of DNX 50 mg HBr hemihydrate 475 DC tablet formulation along with high fat meal</description>
          </group>
          <group group_id="O3">
            <title>600DC High Fat</title>
            <description>Participants received a single oral dose of DNX 50 mg HBr hemihydrate 600 DC tablet formulation along with high fat meal</description>
          </group>
          <group group_id="O4">
            <title>600DC 5%HPMC High Fat</title>
            <description>Participants received a single oral dose of DNX 50 mg HBr hemihydrate 600 DC tablet with 5 percent HPMC formulation along with high fat meal</description>
          </group>
          <group group_id="O5">
            <title>600RC Fasted</title>
            <description>Participants received a single oral dose of DNX 50 mg HBr hemihydrate 600 RC tablet formulation under fasted condition</description>
          </group>
          <group group_id="O6">
            <title>475DC Fasted</title>
            <description>Participants received a single oral dose of DNX 50 mg HBr hemihydrate 475 DC tablet formulation under fasted condition</description>
          </group>
          <group group_id="O7">
            <title>600DC Fasted</title>
            <description>Participants received a single oral dose of DNX 50 mg HBr hemihydrate 600 DC tablet formulation under fasted condition</description>
          </group>
          <group group_id="O8">
            <title>600DC 5%HPMC Fasted</title>
            <description>Participants received a single oral dose of DNX 50 mg HBr hemihydrate 600 DC tablet with 5 percent HPMC formulation under fasted condition</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Vital Signs of Potential Clinical Concern in Part 1</title>
          <description>Vital signs included systolic and diastolic blood pressure, temperature, respiratory rate and pulse rate were measured with participants in semi-supine position after 5 minutes rest.</description>
          <population>mITT Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="8"/>
                <count group_id="O7" value="8"/>
                <count group_id="O8" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With 12-lead Electrocardiogram (ECG) Values of Potential Clinical Concern in Part 1</title>
        <description>Single 12-lead ECGs were obtained using an ECG machine that automatically calculated the heart rate and measured PR, QRS, and QT intervals, and QT interval corrected by Fridericia's formula (QTcF). Number of participants with 12-lead ECG values of potential clinical concern in Part 1 are presented.</description>
        <time_frame>Up to 29 days in Part 1</time_frame>
        <population>mITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>600RC High Fat</title>
            <description>Participants received a single oral dose of DNX 50 mg HBr hemihydrate 600 RC tablet formulation along with a high fat meal</description>
          </group>
          <group group_id="O2">
            <title>475DC High Fat</title>
            <description>Participants received a single oral dose of DNX 50 mg HBr hemihydrate 475 DC tablet formulation along with high fat meal</description>
          </group>
          <group group_id="O3">
            <title>600DC High Fat</title>
            <description>Participants received a single oral dose of DNX 50 mg HBr hemihydrate 600 DC tablet formulation along with high fat meal</description>
          </group>
          <group group_id="O4">
            <title>600DC 5%HPMC High Fat</title>
            <description>Participants received a single oral dose of DNX 50 mg HBr hemihydrate 600 DC tablet with 5 percent HPMC formulation along with high fat meal</description>
          </group>
          <group group_id="O5">
            <title>600RC Fasted</title>
            <description>Participants received a single oral dose of DNX 50 mg HBr hemihydrate 600 RC tablet formulation under fasted condition</description>
          </group>
          <group group_id="O6">
            <title>475DC Fasted</title>
            <description>Participants received a single oral dose of DNX 50 mg HBr hemihydrate 475 DC tablet formulation under fasted condition</description>
          </group>
          <group group_id="O7">
            <title>600DC Fasted</title>
            <description>Participants received a single oral dose of DNX 50 mg HBr hemihydrate 600 DC tablet formulation under fasted condition</description>
          </group>
          <group group_id="O8">
            <title>600DC 5%HPMC Fasted</title>
            <description>Participants received a single oral dose of DNX 50 mg HBr hemihydrate 600 DC tablet with 5 percent HPMC formulation under fasted condition</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With 12-lead Electrocardiogram (ECG) Values of Potential Clinical Concern in Part 1</title>
          <description>Single 12-lead ECGs were obtained using an ECG machine that automatically calculated the heart rate and measured PR, QRS, and QT intervals, and QT interval corrected by Fridericia's formula (QTcF). Number of participants with 12-lead ECG values of potential clinical concern in Part 1 are presented.</description>
          <population>mITT Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="8"/>
                <count group_id="O7" value="8"/>
                <count group_id="O8" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Laboratory Values of Potential Clinical Concern in Part 1</title>
        <description>Hematology parameters included platelet count, RBC Count, hemoglobin, hematocrit, MCV, MCH, %Reticulocytes, neutrophils, lymphocytes, monocytes, eosinophils, basophils. Clinical chemistry parameters included potassium aspartate aminotransferase(AST)/Serum Glutamic-Oxaloacetic Transaminase (SGOT), total and direct bilirubin, creatinine, sodium alanine, aminotransferase, (ALT)/ Serum Glutamic-Pyruvic, Transaminase (SGPT), total protein, fasting glucose, calcium, alkaline phosphatase and albumin. Urinalysis included specific gravity, potential of hydrogen (pH), glucose, protein, blood and ketones by dipstick and microscopic examination of urine.</description>
        <time_frame>Up to 29 days in Part 1</time_frame>
        <population>mITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>600RC High Fat</title>
            <description>Participants received a single oral dose of DNX 50 mg HBr hemihydrate 600 RC tablet formulation along with a high fat meal</description>
          </group>
          <group group_id="O2">
            <title>475DC High Fat</title>
            <description>Participants received a single oral dose of DNX 50 mg HBr hemihydrate 475 DC tablet formulation along with high fat meal</description>
          </group>
          <group group_id="O3">
            <title>600DC High Fat</title>
            <description>Participants received a single oral dose of DNX 50 mg HBr hemihydrate 600 DC tablet formulation along with high fat meal</description>
          </group>
          <group group_id="O4">
            <title>600DC 5%HPMC High Fat</title>
            <description>Participants received a single oral dose of DNX 50 mg HBr hemihydrate 600 DC tablet with 5 percent HPMC formulation along with high fat meal</description>
          </group>
          <group group_id="O5">
            <title>600RC Fasted</title>
            <description>Participants received a single oral dose of DNX 50 mg HBr hemihydrate 600 RC tablet formulation under fasted condition</description>
          </group>
          <group group_id="O6">
            <title>475DC Fasted</title>
            <description>Participants received a single oral dose of DNX 50 mg HBr hemihydrate 475 DC tablet formulation under fasted condition</description>
          </group>
          <group group_id="O7">
            <title>600DC Fasted</title>
            <description>Participants received a single oral dose of DNX 50 mg HBr hemihydrate 600 DC tablet formulation under fasted condition</description>
          </group>
          <group group_id="O8">
            <title>600DC 5%HPMC Fasted</title>
            <description>Participants received a single oral dose of DNX 50 mg HBr hemihydrate 600 DC tablet with 5 percent HPMC formulation under fasted condition</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Laboratory Values of Potential Clinical Concern in Part 1</title>
          <description>Hematology parameters included platelet count, RBC Count, hemoglobin, hematocrit, MCV, MCH, %Reticulocytes, neutrophils, lymphocytes, monocytes, eosinophils, basophils. Clinical chemistry parameters included potassium aspartate aminotransferase(AST)/Serum Glutamic-Oxaloacetic Transaminase (SGOT), total and direct bilirubin, creatinine, sodium alanine, aminotransferase, (ALT)/ Serum Glutamic-Pyruvic, Transaminase (SGPT), total protein, fasting glucose, calcium, alkaline phosphatase and albumin. Urinalysis included specific gravity, potential of hydrogen (pH), glucose, protein, blood and ketones by dipstick and microscopic examination of urine.</description>
          <population>mITT Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="8"/>
                <count group_id="O7" value="8"/>
                <count group_id="O8" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Concentration-time Curve From Time 0 to t (AUC [0-t]) of Danirixin for Part 1</title>
        <description>Blood samples were collected at the indicated time points after administration of study treatment to investigate the PK profile of Danirixin. PK parameters were calculated by standard non-compartmental analysis using WinNonlin based on actual sampling times.</description>
        <time_frame>Pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48 hours in Part 1</time_frame>
        <population>PK population. Only those participants with data available at specified time points were analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>600RC High Fat</title>
            <description>Participants received a single oral dose of DNX 50 mg HBr hemihydrate 600 RC tablet formulation along with a high fat meal</description>
          </group>
          <group group_id="O2">
            <title>475DC High Fat</title>
            <description>Participants received a single oral dose of DNX 50 mg HBr hemihydrate 475 DC tablet formulation along with high fat meal</description>
          </group>
          <group group_id="O3">
            <title>600DC High Fat</title>
            <description>Participants received a single oral dose of DNX 50 mg HBr hemihydrate 600 DC tablet formulation along with high fat meal</description>
          </group>
          <group group_id="O4">
            <title>600DC 5%HPMC High Fat</title>
            <description>Participants received a single oral dose of DNX 50 mg HBr hemihydrate 600 DC tablet with 5 percent HPMC formulation along with high fat meal</description>
          </group>
          <group group_id="O5">
            <title>600RC Fasted</title>
            <description>Participants received a single oral dose of DNX 50 mg HBr hemihydrate 600 RC tablet formulation under fasted condition</description>
          </group>
          <group group_id="O6">
            <title>475DC Fasted</title>
            <description>Participants received a single oral dose of DNX 50 mg HBr hemihydrate 475 DC tablet formulation under fasted condition</description>
          </group>
          <group group_id="O7">
            <title>600DC Fasted</title>
            <description>Participants received a single oral dose of DNX 50 mg HBr hemihydrate 600 DC tablet formulation under fasted condition</description>
          </group>
          <group group_id="O8">
            <title>600DC 5%HPMC Fasted</title>
            <description>Participants received a single oral dose of DNX 50 mg HBr hemihydrate 600 DC tablet with 5 percent HPMC formulation under fasted condition</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Concentration-time Curve From Time 0 to t (AUC [0-t]) of Danirixin for Part 1</title>
          <description>Blood samples were collected at the indicated time points after administration of study treatment to investigate the PK profile of Danirixin. PK parameters were calculated by standard non-compartmental analysis using WinNonlin based on actual sampling times.</description>
          <population>PK population. Only those participants with data available at specified time points were analyzed</population>
          <units>Hours*nanograms/milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="7"/>
                <count group_id="O6" value="8"/>
                <count group_id="O7" value="8"/>
                <count group_id="O8" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5515.9" spread="24.54"/>
                    <measurement group_id="O2" value="5573.6" spread="17.65"/>
                    <measurement group_id="O3" value="5524.7" spread="22.15"/>
                    <measurement group_id="O4" value="5287.0" spread="28.27"/>
                    <measurement group_id="O5" value="11480.1" spread="28.07"/>
                    <measurement group_id="O6" value="10977.2" spread="30.52"/>
                    <measurement group_id="O7" value="10636.5" spread="32.09"/>
                    <measurement group_id="O8" value="11015.8" spread="28.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Concentration-time Curve From Time 0 to 24 Hours Post-dose (AUC [0-24]) of Danirixin for Part 1</title>
        <description>Blood samples were collected at the indicated time points after administration of study treatment to investigate the PK profile of Danirixin. PK parameters were calculated by standard non-compartmental analysis using WinNonlin based on actual sampling times.</description>
        <time_frame>Pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48 hours in Part 1</time_frame>
        <population>PK population. Only those participants with data available at specified time points were analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>600RC High Fat</title>
            <description>Participants received a single oral dose of DNX 50 mg HBr hemihydrate 600 RC tablet formulation along with a high fat meal</description>
          </group>
          <group group_id="O2">
            <title>475DC High Fat</title>
            <description>Participants received a single oral dose of DNX 50 mg HBr hemihydrate 475 DC tablet formulation along with high fat meal</description>
          </group>
          <group group_id="O3">
            <title>600DC High Fat</title>
            <description>Participants received a single oral dose of DNX 50 mg HBr hemihydrate 600 DC tablet formulation along with high fat meal</description>
          </group>
          <group group_id="O4">
            <title>600DC 5%HPMC High Fat</title>
            <description>Participants received a single oral dose of DNX 50 mg HBr hemihydrate 600 DC tablet with 5 percent HPMC formulation along with high fat meal</description>
          </group>
          <group group_id="O5">
            <title>600RC Fasted</title>
            <description>Participants received a single oral dose of DNX 50 mg HBr hemihydrate 600 RC tablet formulation under fasted condition</description>
          </group>
          <group group_id="O6">
            <title>475DC Fasted</title>
            <description>Participants received a single oral dose of DNX 50 mg HBr hemihydrate 475 DC tablet formulation under fasted condition</description>
          </group>
          <group group_id="O7">
            <title>600DC Fasted</title>
            <description>Participants received a single oral dose of DNX 50 mg HBr hemihydrate 600 DC tablet formulation under fasted condition</description>
          </group>
          <group group_id="O8">
            <title>600DC 5%HPMC Fasted</title>
            <description>Participants received a single oral dose of DNX 50 mg HBr hemihydrate 600 DC tablet with 5 percent HPMC formulation under fasted condition</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Concentration-time Curve From Time 0 to 24 Hours Post-dose (AUC [0-24]) of Danirixin for Part 1</title>
          <description>Blood samples were collected at the indicated time points after administration of study treatment to investigate the PK profile of Danirixin. PK parameters were calculated by standard non-compartmental analysis using WinNonlin based on actual sampling times.</description>
          <population>PK population. Only those participants with data available at specified time points were analyzed</population>
          <units>Hours*nanograms/milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="7"/>
                <count group_id="O6" value="8"/>
                <count group_id="O7" value="8"/>
                <count group_id="O8" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4919.5" spread="27.19"/>
                    <measurement group_id="O2" value="4952.0" spread="18.25"/>
                    <measurement group_id="O3" value="4984.8" spread="24.27"/>
                    <measurement group_id="O4" value="4705.2" spread="27.96"/>
                    <measurement group_id="O5" value="10744.8" spread="26.07"/>
                    <measurement group_id="O6" value="10419.9" spread="27.78"/>
                    <measurement group_id="O7" value="10029.3" spread="32.19"/>
                    <measurement group_id="O8" value="10319.9" spread="26.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Occurrence of Cmax (Tmax) of Danirixin for Part 1</title>
        <description>Blood samples were collected at the indicated time points after administration of study treatment to investigate the PK profile of Danirixin. PK parameters were calculated by standard non-compartmental analysis using WinNonlin based on actual sampling times.</description>
        <time_frame>Pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48 hours in Part 1</time_frame>
        <population>PK population. Only those participants with data available at specified time points were analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>600RC High Fat</title>
            <description>Participants received a single oral dose of DNX 50 mg HBr hemihydrate 600 RC tablet formulation along with a high fat meal</description>
          </group>
          <group group_id="O2">
            <title>475DC High Fat</title>
            <description>Participants received a single oral dose of DNX 50 mg HBr hemihydrate 475 DC tablet formulation along with high fat meal</description>
          </group>
          <group group_id="O3">
            <title>600DC High Fat</title>
            <description>Participants received a single oral dose of DNX 50 mg HBr hemihydrate 600 DC tablet formulation along with high fat meal</description>
          </group>
          <group group_id="O4">
            <title>600DC 5%HPMC High Fat</title>
            <description>Participants received a single oral dose of DNX 50 mg HBr hemihydrate 600 DC tablet with 5 percent HPMC formulation along with high fat meal</description>
          </group>
          <group group_id="O5">
            <title>600RC Fasted</title>
            <description>Participants received a single oral dose of DNX 50 mg HBr hemihydrate 600 RC tablet formulation under fasted condition</description>
          </group>
          <group group_id="O6">
            <title>475DC Fasted</title>
            <description>Participants received a single oral dose of DNX 50 mg HBr hemihydrate 475 DC tablet formulation under fasted condition</description>
          </group>
          <group group_id="O7">
            <title>600DC Fasted</title>
            <description>Participants received a single oral dose of DNX 50 mg HBr hemihydrate 600 DC tablet formulation under fasted condition</description>
          </group>
          <group group_id="O8">
            <title>600DC 5%HPMC Fasted</title>
            <description>Participants received a single oral dose of DNX 50 mg HBr hemihydrate 600 DC tablet with 5 percent HPMC formulation under fasted condition</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Occurrence of Cmax (Tmax) of Danirixin for Part 1</title>
          <description>Blood samples were collected at the indicated time points after administration of study treatment to investigate the PK profile of Danirixin. PK parameters were calculated by standard non-compartmental analysis using WinNonlin based on actual sampling times.</description>
          <population>PK population. Only those participants with data available at specified time points were analyzed</population>
          <units>Hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="7"/>
                <count group_id="O6" value="8"/>
                <count group_id="O7" value="8"/>
                <count group_id="O8" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.897" spread="0.9894"/>
                    <measurement group_id="O2" value="3.653" spread="0.5089"/>
                    <measurement group_id="O3" value="3.585" spread="1.2942"/>
                    <measurement group_id="O4" value="4.158" spread="1.3556"/>
                    <measurement group_id="O5" value="1.165" spread="0.3794"/>
                    <measurement group_id="O6" value="1.331" spread="0.7536"/>
                    <measurement group_id="O7" value="1.214" spread="0.2669"/>
                    <measurement group_id="O8" value="1.342" spread="0.3768"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Terminal Half-life (t1/2) of Danirixin for Part 1</title>
        <description>Blood samples were collected at the indicated time points after administration of study treatment to investigate the PK profile of Danirixin. PK parameters were calculated by standard non-compartmental analysis using WinNonlin based on actual sampling times.</description>
        <time_frame>Pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48 hours in Part 1</time_frame>
        <population>PK population. Only those participants with data available at specified time points were analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>600RC High Fat</title>
            <description>Participants received a single oral dose of DNX 50 mg HBr hemihydrate 600 RC tablet formulation along with a high fat meal</description>
          </group>
          <group group_id="O2">
            <title>475DC High Fat</title>
            <description>Participants received a single oral dose of DNX 50 mg HBr hemihydrate 475 DC tablet formulation along with high fat meal</description>
          </group>
          <group group_id="O3">
            <title>600DC High Fat</title>
            <description>Participants received a single oral dose of DNX 50 mg HBr hemihydrate 600 DC tablet formulation along with high fat meal</description>
          </group>
          <group group_id="O4">
            <title>600DC 5%HPMC High Fat</title>
            <description>Participants received a single oral dose of DNX 50 mg HBr hemihydrate 600 DC tablet with 5 percent HPMC formulation along with high fat meal</description>
          </group>
          <group group_id="O5">
            <title>600RC Fasted</title>
            <description>Participants received a single oral dose of DNX 50 mg HBr hemihydrate 600 RC tablet formulation under fasted condition</description>
          </group>
          <group group_id="O6">
            <title>475DC Fasted</title>
            <description>Participants received a single oral dose of DNX 50 mg HBr hemihydrate 475 DC tablet formulation under fasted condition</description>
          </group>
          <group group_id="O7">
            <title>600DC Fasted</title>
            <description>Participants received a single oral dose of DNX 50 mg HBr hemihydrate 600 DC tablet formulation under fasted condition</description>
          </group>
          <group group_id="O8">
            <title>600DC 5%HPMC Fasted</title>
            <description>Participants received a single oral dose of DNX 50 mg HBr hemihydrate 600 DC tablet with 5 percent HPMC formulation under fasted condition</description>
          </group>
        </group_list>
        <measure>
          <title>Terminal Half-life (t1/2) of Danirixin for Part 1</title>
          <description>Blood samples were collected at the indicated time points after administration of study treatment to investigate the PK profile of Danirixin. PK parameters were calculated by standard non-compartmental analysis using WinNonlin based on actual sampling times.</description>
          <population>PK population. Only those participants with data available at specified time points were analyzed</population>
          <units>Hours</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="7"/>
                <count group_id="O7" value="8"/>
                <count group_id="O8" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.638" spread="17.60"/>
                    <measurement group_id="O2" value="10.904" spread="19.33"/>
                    <measurement group_id="O3" value="8.916" spread="29.74"/>
                    <measurement group_id="O4" value="9.888" spread="26.18"/>
                    <measurement group_id="O5" value="8.298" spread="36.18"/>
                    <measurement group_id="O6" value="9.498" spread="26.76"/>
                    <measurement group_id="O7" value="9.391" spread="45.40"/>
                    <measurement group_id="O8" value="9.107" spread="29.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Last Quantifiable Concentration (Tlast) of the Blood Concentration of Danirixin for Part 1</title>
        <description>Blood samples were collected at the indicated time points after administration of study treatment to investigate the PK profile of Danirixin. PK parameters were calculated by standard non-compartmental analysis using WinNonlin based on actual sampling times.</description>
        <time_frame>Pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48 hours in Part 1</time_frame>
        <population>PK population. Only those participants with data available at specified time points were analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>600RC High Fat</title>
            <description>Participants received a single oral dose of DNX 50 mg HBr hemihydrate 600 RC tablet formulation along with a high fat meal</description>
          </group>
          <group group_id="O2">
            <title>475DC High Fat</title>
            <description>Participants received a single oral dose of DNX 50 mg HBr hemihydrate 475 DC tablet formulation along with high fat meal</description>
          </group>
          <group group_id="O3">
            <title>600DC High Fat</title>
            <description>Participants received a single oral dose of DNX 50 mg HBr hemihydrate 600 DC tablet formulation along with high fat meal</description>
          </group>
          <group group_id="O4">
            <title>600DC 5%HPMC High Fat</title>
            <description>Participants received a single oral dose of DNX 50 mg HBr hemihydrate 600 DC tablet with 5 percent HPMC formulation along with high fat meal</description>
          </group>
          <group group_id="O5">
            <title>600RC Fasted</title>
            <description>Participants received a single oral dose of DNX 50 mg HBr hemihydrate 600 RC tablet formulation under fasted condition</description>
          </group>
          <group group_id="O6">
            <title>475DC Fasted</title>
            <description>Participants received a single oral dose of DNX 50 mg HBr hemihydrate 475 DC tablet formulation under fasted condition</description>
          </group>
          <group group_id="O7">
            <title>600DC Fasted</title>
            <description>Participants received a single oral dose of DNX 50 mg HBr hemihydrate 600 DC tablet formulation under fasted condition</description>
          </group>
          <group group_id="O8">
            <title>600DC 5%HPMC Fasted</title>
            <description>Participants received a single oral dose of DNX 50 mg HBr hemihydrate 600 DC tablet with 5 percent HPMC formulation under fasted condition</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Last Quantifiable Concentration (Tlast) of the Blood Concentration of Danirixin for Part 1</title>
          <description>Blood samples were collected at the indicated time points after administration of study treatment to investigate the PK profile of Danirixin. PK parameters were calculated by standard non-compartmental analysis using WinNonlin based on actual sampling times.</description>
          <population>PK population. Only those participants with data available at specified time points were analyzed</population>
          <units>Hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="7"/>
                <count group_id="O6" value="8"/>
                <count group_id="O7" value="8"/>
                <count group_id="O8" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.660" spread="0.2178"/>
                    <measurement group_id="O2" value="47.587" spread="0.2200"/>
                    <measurement group_id="O3" value="44.657" spread="8.3551"/>
                    <measurement group_id="O4" value="44.757" spread="8.3813"/>
                    <measurement group_id="O5" value="44.372" spread="8.9730"/>
                    <measurement group_id="O6" value="41.789" spread="10.9667"/>
                    <measurement group_id="O7" value="41.699" spread="10.9179"/>
                    <measurement group_id="O8" value="44.531" spread="8.3335"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Lag Time Before Observation of Drug Concentrations in Sampled Matrix (Tlag) of Danirixin for Part 1</title>
        <description>Blood samples were collected at the indicated time points after administration of study treatment to investigate the PK profile of Danirixin. PK parameters were calculated by standard non-compartmental analysis using WinNonlin based on actual sampling times.</description>
        <time_frame>Pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48 hours in Part 1</time_frame>
        <population>PK population. Only those participants with data available at specified time points were analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>600RC High Fat</title>
            <description>Participants received a single oral dose of DNX 50 mg HBr hemihydrate 600 RC tablet formulation along with a high fat meal</description>
          </group>
          <group group_id="O2">
            <title>475DC High Fat</title>
            <description>Participants received a single oral dose of DNX 50 mg HBr hemihydrate 475 DC tablet formulation along with high fat meal</description>
          </group>
          <group group_id="O3">
            <title>600DC High Fat</title>
            <description>Participants received a single oral dose of DNX 50 mg HBr hemihydrate 600 DC tablet formulation along with high fat meal</description>
          </group>
          <group group_id="O4">
            <title>600DC 5%HPMC High Fat</title>
            <description>Participants received a single oral dose of DNX 50 mg HBr hemihydrate 600 DC tablet with 5 percent HPMC formulation along with high fat meal</description>
          </group>
          <group group_id="O5">
            <title>600RC Fasted</title>
            <description>Participants received a single oral dose of DNX 50 mg HBr hemihydrate 600 RC tablet formulation under fasted condition</description>
          </group>
          <group group_id="O6">
            <title>475DC Fasted</title>
            <description>Participants received a single oral dose of DNX 50 mg HBr hemihydrate 475 DC tablet formulation under fasted condition</description>
          </group>
          <group group_id="O7">
            <title>600DC Fasted</title>
            <description>Participants received a single oral dose of DNX 50 mg HBr hemihydrate 600 DC tablet formulation under fasted condition</description>
          </group>
          <group group_id="O8">
            <title>600DC 5%HPMC Fasted</title>
            <description>Participants received a single oral dose of DNX 50 mg HBr hemihydrate 600 DC tablet with 5 percent HPMC formulation under fasted condition</description>
          </group>
        </group_list>
        <measure>
          <title>Lag Time Before Observation of Drug Concentrations in Sampled Matrix (Tlag) of Danirixin for Part 1</title>
          <description>Blood samples were collected at the indicated time points after administration of study treatment to investigate the PK profile of Danirixin. PK parameters were calculated by standard non-compartmental analysis using WinNonlin based on actual sampling times.</description>
          <population>PK population. Only those participants with data available at specified time points were analyzed</population>
          <units>Hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="7"/>
                <count group_id="O6" value="8"/>
                <count group_id="O7" value="8"/>
                <count group_id="O8" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.323" spread="0.3812"/>
                    <measurement group_id="O2" value="0.383" spread="0.5917"/>
                    <measurement group_id="O3" value="0.383" spread="0.5918"/>
                    <measurement group_id="O4" value="0.511" spread="0.6661"/>
                    <measurement group_id="O5" value="0.000" spread="0.000"/>
                    <measurement group_id="O6" value="0.065" spread="0.1830"/>
                    <measurement group_id="O7" value="0.000" spread="0.0000"/>
                    <measurement group_id="O8" value="0.000" spread="0.0000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Concentration-time Curve From Time 0 to Infinity (AUC [0-inf]) of Danirixin for Part 2</title>
        <description>Blood samples were collected at the indicated time points after administration of study treatment to investigate the PK profile of Danirixin. PK parameters were calculated by standard non-compartmental analysis using WinNonlin based on actual sampling times.</description>
        <time_frame>Pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48 hours in Part 2</time_frame>
        <population>PK population. Only those participants with data available at specified time points were analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>475DC-Fasted</title>
            <description>Participants received a single dose of DNX 50 mg HBr hemihydrate 475 DC tablet formulation in fasted state</description>
          </group>
          <group group_id="O2">
            <title>475DC-Normal Meal</title>
            <description>Participants received DNX 50 mg HBr hemihydrate 475 DC formulation along with normal meal</description>
          </group>
          <group group_id="O3">
            <title>475DC-High Fat</title>
            <description>Participants received DNX 50 mg HBr hemihydrate 475 DC formulation along with high fat meal</description>
          </group>
          <group group_id="O4">
            <title>475DC-MONO High Fat</title>
            <description>Participants received DNX 50 mg HBr monohydrate 475 DC with 5 percent HPMC formulation along with high fat meal</description>
          </group>
          <group group_id="O5">
            <title>475DC Fasted OMP</title>
            <description>Participants received DNX 50 mg HBr hemihydrate 475 DC formulation and OMP under fasted condition</description>
          </group>
          <group group_id="O6">
            <title>475DC Normal Meal OMP</title>
            <description>Participants received DNX 50 mg HBr hemihydrate 475 DC formulation and OMP along with normal meal</description>
          </group>
          <group group_id="O7">
            <title>475DC High Fat OMP</title>
            <description>Participants received DNX 50 mg HBr hemihydrate 475 DC formulation and OMP along with high fat meal</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Concentration-time Curve From Time 0 to Infinity (AUC [0-inf]) of Danirixin for Part 2</title>
          <description>Blood samples were collected at the indicated time points after administration of study treatment to investigate the PK profile of Danirixin. PK parameters were calculated by standard non-compartmental analysis using WinNonlin based on actual sampling times.</description>
          <population>PK population. Only those participants with data available at specified time points were analyzed</population>
          <units>Hours*nanograms/milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="11"/>
                <count group_id="O5" value="9"/>
                <count group_id="O6" value="10"/>
                <count group_id="O7" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12426.4" spread="35.85"/>
                    <measurement group_id="O2" value="7761.2" spread="41.31"/>
                    <measurement group_id="O3" value="8136.7" spread="32.85"/>
                    <measurement group_id="O4" value="7356.4" spread="34.65"/>
                    <measurement group_id="O5" value="14615.2" spread="24.23"/>
                    <measurement group_id="O6" value="10185.0" spread="34.57"/>
                    <measurement group_id="O7" value="8782.5" spread="45.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Concentration-time Curve From Time 0 to t (AUC [0-t]) of Danirixin for Part 2</title>
        <description>Blood samples were collected at the indicated time points after administration of study treatment to investigate the PK profile of Danirixin. PK parameters were calculated by standard non-compartmental analysis using WinNonlin based on actual sampling times.</description>
        <time_frame>Pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48 hours in Part 2</time_frame>
        <population>PK population. Only those participants with data available at specified time points were analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>475DC-Fasted</title>
            <description>Participants received a single dose of DNX 50 mg HBr hemihydrate 475 DC tablet formulation in fasted state</description>
          </group>
          <group group_id="O2">
            <title>475DC-Normal Meal</title>
            <description>Participants received DNX 50 mg HBr hemihydrate 475 DC formulation along with normal meal</description>
          </group>
          <group group_id="O3">
            <title>475DC-High Fat</title>
            <description>Participants received DNX 50 mg HBr hemihydrate 475 DC formulation along with high fat meal</description>
          </group>
          <group group_id="O4">
            <title>475DC-MONO High Fat</title>
            <description>Participants received DNX 50 mg HBr monohydrate 475 DC with 5 percent HPMC formulation along with high fat meal</description>
          </group>
          <group group_id="O5">
            <title>475DC Fasted OMP</title>
            <description>Participants received DNX 50 mg HBr hemihydrate 475 DC formulation and OMP under fasted condition</description>
          </group>
          <group group_id="O6">
            <title>475DC Normal Meal OMP</title>
            <description>Participants received DNX 50 mg HBr hemihydrate 475 DC formulation and OMP along with normal meal</description>
          </group>
          <group group_id="O7">
            <title>475DC High Fat OMP</title>
            <description>Participants received DNX 50 mg HBr hemihydrate 475 DC formulation and OMP along with high fat meal</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Concentration-time Curve From Time 0 to t (AUC [0-t]) of Danirixin for Part 2</title>
          <description>Blood samples were collected at the indicated time points after administration of study treatment to investigate the PK profile of Danirixin. PK parameters were calculated by standard non-compartmental analysis using WinNonlin based on actual sampling times.</description>
          <population>PK population. Only those participants with data available at specified time points were analyzed</population>
          <units>Hours*nanograms/milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="11"/>
                <count group_id="O6" value="11"/>
                <count group_id="O7" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12026.9" spread="37.00"/>
                    <measurement group_id="O2" value="7484.2" spread="39.37"/>
                    <measurement group_id="O3" value="7757.2" spread="31.77"/>
                    <measurement group_id="O4" value="6986.9" spread="32.54"/>
                    <measurement group_id="O5" value="12903.9" spread="37.02"/>
                    <measurement group_id="O6" value="9023.8" spread="42.46"/>
                    <measurement group_id="O7" value="7885.4" spread="46.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Concentration-time Curve From Time 0 to 24 Hours (AUC [0-24]) of Danirixin for Part 2</title>
        <description>Blood samples were collected at the indicated time points after administration of study treatment to investigate the PK profile of Danirixin. PK parameters were calculated by standard non-compartmental analysis using WinNonlin based on actual sampling times.</description>
        <time_frame>Pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48 hours in Part 2</time_frame>
        <population>PK population. Only those participants with data available at specified time points were analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>475DC-Fasted</title>
            <description>Participants received a single dose of DNX 50 mg HBr hemihydrate 475 DC tablet formulation in fasted state</description>
          </group>
          <group group_id="O2">
            <title>475DC-Normal Meal</title>
            <description>Participants received DNX 50 mg HBr hemihydrate 475 DC formulation along with normal meal</description>
          </group>
          <group group_id="O3">
            <title>475DC-High Fat</title>
            <description>Participants received DNX 50 mg HBr hemihydrate 475 DC formulation along with high fat meal</description>
          </group>
          <group group_id="O4">
            <title>475DC-MONO High Fat</title>
            <description>Participants received DNX 50 mg HBr monohydrate 475 DC with 5 percent HPMC formulation along with high fat meal</description>
          </group>
          <group group_id="O5">
            <title>475DC Fasted OMP</title>
            <description>Participants received DNX 50 mg HBr hemihydrate 475 DC formulation and OMP under fasted condition</description>
          </group>
          <group group_id="O6">
            <title>475DC Normal Meal OMP</title>
            <description>Participants received DNX 50 mg HBr hemihydrate 475 DC formulation and OMP along with normal meal</description>
          </group>
          <group group_id="O7">
            <title>475DC High Fat OMP</title>
            <description>Participants received DNX 50 mg HBr hemihydrate 475 DC formulation and OMP along with high fat meal</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Concentration-time Curve From Time 0 to 24 Hours (AUC [0-24]) of Danirixin for Part 2</title>
          <description>Blood samples were collected at the indicated time points after administration of study treatment to investigate the PK profile of Danirixin. PK parameters were calculated by standard non-compartmental analysis using WinNonlin based on actual sampling times.</description>
          <population>PK population. Only those participants with data available at specified time points were analyzed</population>
          <units>Hours*nanograms/milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="10"/>
                <count group_id="O6" value="10"/>
                <count group_id="O7" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11096.7" spread="36.64"/>
                    <measurement group_id="O2" value="6482.2" spread="37.93"/>
                    <measurement group_id="O3" value="6706.6" spread="28.49"/>
                    <measurement group_id="O4" value="6187.1" spread="30.41"/>
                    <measurement group_id="O5" value="12762.9" spread="23.58"/>
                    <measurement group_id="O6" value="8681.0" spread="32.68"/>
                    <measurement group_id="O7" value="7590.8" spread="37.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Observed Concentration (Cmax) of Danirixin for Part 2</title>
        <description>Blood samples were collected at the indicated time points after administration of study treatment to investigate the PK profile of Danirixin. PK parameters were calculated by standard non-compartmental analysis using WinNonlin based on actual sampling times.</description>
        <time_frame>Pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48 hours in Part 2</time_frame>
        <population>PK population. Only those participants with data available at specified time points were analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>475DC-Fasted</title>
            <description>Participants received a single dose of DNX 50 mg HBr hemihydrate 475 DC tablet formulation in fasted state</description>
          </group>
          <group group_id="O2">
            <title>475DC-Normal Meal</title>
            <description>Participants received DNX 50 mg HBr hemihydrate 475 DC formulation along with normal meal</description>
          </group>
          <group group_id="O3">
            <title>475DC-High Fat</title>
            <description>Participants received DNX 50 mg HBr hemihydrate 475 DC formulation along with high fat meal</description>
          </group>
          <group group_id="O4">
            <title>475DC-MONO High Fat</title>
            <description>Participants received DNX 50 mg HBr monohydrate 475 DC with 5 percent HPMC formulation along with high fat meal</description>
          </group>
          <group group_id="O5">
            <title>475DC Fasted OMP</title>
            <description>Participants received DNX 50 mg HBr hemihydrate 475 DC formulation and OMP under fasted condition</description>
          </group>
          <group group_id="O6">
            <title>475DC Normal Meal OMP</title>
            <description>Participants received DNX 50 mg HBr hemihydrate 475 DC formulation and OMP along with normal meal</description>
          </group>
          <group group_id="O7">
            <title>475DC High Fat OMP</title>
            <description>Participants received DNX 50 mg HBr hemihydrate 475 DC formulation and OMP along with high fat meal</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Observed Concentration (Cmax) of Danirixin for Part 2</title>
          <description>Blood samples were collected at the indicated time points after administration of study treatment to investigate the PK profile of Danirixin. PK parameters were calculated by standard non-compartmental analysis using WinNonlin based on actual sampling times.</description>
          <population>PK population. Only those participants with data available at specified time points were analyzed</population>
          <units>Nanograms/milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="11"/>
                <count group_id="O6" value="11"/>
                <count group_id="O7" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2317.4" spread="44.90"/>
                    <measurement group_id="O2" value="989.9" spread="47.91"/>
                    <measurement group_id="O3" value="969.9" spread="37.80"/>
                    <measurement group_id="O4" value="1019.8" spread="38.90"/>
                    <measurement group_id="O5" value="2292.5" spread="43.18"/>
                    <measurement group_id="O6" value="1389.7" spread="43.59"/>
                    <measurement group_id="O7" value="1132.5" spread="35.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Maximum Observed Concentration (Tmax) of Danirixin for Part 2</title>
        <description>Blood samples were collected at the indicated time points after administration of study treatment to investigate the PK profile of Danirixin. PK parameters were calculated by standard non-compartmental analysis using WinNonlin based on actual sampling times.</description>
        <time_frame>Pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48 hours in Part 2</time_frame>
        <population>PK population. Only those participants with data available at specified time points were analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>475DC-Fasted</title>
            <description>Participants received a single dose of DNX 50 mg HBr hemihydrate 475 DC tablet formulation in fasted state</description>
          </group>
          <group group_id="O2">
            <title>475DC-Normal Meal</title>
            <description>Participants received DNX 50 mg HBr hemihydrate 475 DC formulation along with normal meal</description>
          </group>
          <group group_id="O3">
            <title>475DC-High Fat</title>
            <description>Participants received DNX 50 mg HBr hemihydrate 475 DC formulation along with high fat meal</description>
          </group>
          <group group_id="O4">
            <title>475DC-MONO High Fat</title>
            <description>Participants received DNX 50 mg HBr monohydrate 475 DC with 5 percent HPMC formulation along with high fat meal</description>
          </group>
          <group group_id="O5">
            <title>475DC Fasted OMP</title>
            <description>Participants received DNX 50 mg HBr hemihydrate 475 DC formulation and OMP under fasted condition</description>
          </group>
          <group group_id="O6">
            <title>475DC Normal Meal OMP</title>
            <description>Participants received DNX 50 mg HBr hemihydrate 475 DC formulation and OMP along with normal meal</description>
          </group>
          <group group_id="O7">
            <title>475DC High Fat OMP</title>
            <description>Participants received DNX 50 mg HBr hemihydrate 475 DC formulation and OMP along with high fat meal</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Maximum Observed Concentration (Tmax) of Danirixin for Part 2</title>
          <description>Blood samples were collected at the indicated time points after administration of study treatment to investigate the PK profile of Danirixin. PK parameters were calculated by standard non-compartmental analysis using WinNonlin based on actual sampling times.</description>
          <population>PK population. Only those participants with data available at specified time points were analyzed</population>
          <units>Hours</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="11"/>
                <count group_id="O6" value="11"/>
                <count group_id="O7" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.271" spread="0.3374"/>
                    <measurement group_id="O2" value="3.749" spread="0.6458"/>
                    <measurement group_id="O3" value="4.150" spread="1.5008"/>
                    <measurement group_id="O4" value="3.355" spread="1.3724"/>
                    <measurement group_id="O5" value="1.978" spread="0.8770"/>
                    <measurement group_id="O6" value="2.887" spread="0.7802"/>
                    <measurement group_id="O7" value="3.752" spread="1.7384"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Terminal Half-life (t1/2) of Danirixin for Part 2</title>
        <description>Blood samples were collected at the indicated time points after administration of study treatment to investigate the PK profile of Danirixin. PK parameters were calculated by standard non-compartmental analysis using WinNonlin based on actual sampling times.</description>
        <time_frame>Pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48 hours in Part 2</time_frame>
        <population>PK population. Only those participants with data available at specified time points were analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>475DC-Fasted</title>
            <description>Participants received a single dose of DNX 50 mg HBr hemihydrate 475 DC tablet formulation in fasted state</description>
          </group>
          <group group_id="O2">
            <title>475DC-Normal Meal</title>
            <description>Participants received DNX 50 mg HBr hemihydrate 475 DC formulation along with normal meal</description>
          </group>
          <group group_id="O3">
            <title>475DC-High Fat</title>
            <description>Participants received DNX 50 mg HBr hemihydrate 475 DC formulation along with high fat meal</description>
          </group>
          <group group_id="O4">
            <title>475DC-MONO High Fat</title>
            <description>Participants received DNX 50 mg HBr monohydrate 475 DC with 5 percent HPMC formulation along with high fat meal</description>
          </group>
          <group group_id="O5">
            <title>475DC Fasted OMP</title>
            <description>Participants received DNX 50 mg HBr hemihydrate 475 DC formulation and OMP under fasted condition</description>
          </group>
          <group group_id="O6">
            <title>475DC Normal Meal OMP</title>
            <description>Participants received DNX 50 mg HBr hemihydrate 475 DC formulation and OMP along with normal meal</description>
          </group>
          <group group_id="O7">
            <title>475DC High Fat OMP</title>
            <description>Participants received DNX 50 mg HBr hemihydrate 475 DC formulation and OMP along with high fat meal</description>
          </group>
        </group_list>
        <measure>
          <title>Terminal Half-life (t1/2) of Danirixin for Part 2</title>
          <description>Blood samples were collected at the indicated time points after administration of study treatment to investigate the PK profile of Danirixin. PK parameters were calculated by standard non-compartmental analysis using WinNonlin based on actual sampling times.</description>
          <population>PK population. Only those participants with data available at specified time points were analyzed</population>
          <units>Hours</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="11"/>
                <count group_id="O5" value="9"/>
                <count group_id="O6" value="10"/>
                <count group_id="O7" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.647" spread="26.80"/>
                    <measurement group_id="O2" value="11.424" spread="21.51"/>
                    <measurement group_id="O3" value="11.484" spread="11.21"/>
                    <measurement group_id="O4" value="11.652" spread="20.01"/>
                    <measurement group_id="O5" value="11.304" spread="15.02"/>
                    <measurement group_id="O6" value="10.913" spread="24.37"/>
                    <measurement group_id="O7" value="8.975" spread="33.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Last Quantifiable Concentration (Tlast) of the Blood Concentration of Danirixin for Part 2</title>
        <description>Blood samples were collected at the indicated time points after administration of study treatment to investigate the PK profile of Danirixin. PK parameters were calculated by standard non-compartmental analysis using WinNonlin based on actual sampling times.</description>
        <time_frame>Pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48 hours in Part 2</time_frame>
        <population>PK population. Only those participants with data available at specified time points were analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>475DC-Fasted</title>
            <description>Participants received a single dose of DNX 50 mg HBr hemihydrate 475 DC tablet formulation in fasted state</description>
          </group>
          <group group_id="O2">
            <title>475DC-Normal Meal</title>
            <description>Participants received DNX 50 mg HBr hemihydrate 475 DC formulation along with normal meal</description>
          </group>
          <group group_id="O3">
            <title>475DC-High Fat</title>
            <description>Participants received DNX 50 mg HBr hemihydrate 475 DC formulation along with high fat meal</description>
          </group>
          <group group_id="O4">
            <title>475DC-MONO High Fat</title>
            <description>Participants received DNX 50 mg HBr monohydrate 475 DC with 5 percent HPMC formulation along with high fat meal</description>
          </group>
          <group group_id="O5">
            <title>475DC Fasted OMP</title>
            <description>Participants received DNX 50 mg HBr hemihydrate 475 DC formulation and OMP under fasted condition</description>
          </group>
          <group group_id="O6">
            <title>475DC Normal Meal OMP</title>
            <description>Participants received DNX 50 mg HBr hemihydrate 475 DC formulation and OMP along with normal meal</description>
          </group>
          <group group_id="O7">
            <title>475DC High Fat OMP</title>
            <description>Participants received DNX 50 mg HBr hemihydrate 475 DC formulation and OMP along with high fat meal</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Last Quantifiable Concentration (Tlast) of the Blood Concentration of Danirixin for Part 2</title>
          <description>Blood samples were collected at the indicated time points after administration of study treatment to investigate the PK profile of Danirixin. PK parameters were calculated by standard non-compartmental analysis using WinNonlin based on actual sampling times.</description>
          <population>PK population. Only those participants with data available at specified time points were analyzed</population>
          <units>Hours</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="11"/>
                <count group_id="O6" value="11"/>
                <count group_id="O7" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.139" spread="6.6767"/>
                    <measurement group_id="O2" value="47.144" spread="0.4440"/>
                    <measurement group_id="O3" value="47.200" spread="0.4262"/>
                    <measurement group_id="O4" value="46.741" spread="0.4843"/>
                    <measurement group_id="O5" value="45.217" spread="7.0764"/>
                    <measurement group_id="O6" value="45.242" spread="7.0723"/>
                    <measurement group_id="O7" value="40.869" spread="10.8896"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Lag Time Before Observable Concentration (Tlag) of Danirixin for Part 2</title>
        <description>Blood samples were collected at the indicated time points after administration of study treatment to investigate the PK profile of Danirixin. PK parameters were calculated by standard non-compartmental analysis using WinNonlin based on actual sampling times.</description>
        <time_frame>Pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48 hours in Part 2</time_frame>
        <population>PK population. Only those participants with data available at specified time points were analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>475DC-Fasted</title>
            <description>Participants received a single dose of DNX 50 mg HBr hemihydrate 475 DC tablet formulation in fasted state</description>
          </group>
          <group group_id="O2">
            <title>475DC-Normal Meal</title>
            <description>Participants received DNX 50 mg HBr hemihydrate 475 DC formulation along with normal meal</description>
          </group>
          <group group_id="O3">
            <title>475DC-High Fat</title>
            <description>Participants received DNX 50 mg HBr hemihydrate 475 DC formulation along with high fat meal</description>
          </group>
          <group group_id="O4">
            <title>475DC-MONO High Fat</title>
            <description>Participants received DNX 50 mg HBr monohydrate 475 DC with 5 percent HPMC formulation along with high fat meal</description>
          </group>
          <group group_id="O5">
            <title>475DC Fasted OMP</title>
            <description>Participants received DNX 50 mg HBr hemihydrate 475 DC formulation and OMP under fasted condition</description>
          </group>
          <group group_id="O6">
            <title>475DC Normal Meal OMP</title>
            <description>Participants received DNX 50 mg HBr hemihydrate 475 DC formulation and OMP along with normal meal</description>
          </group>
          <group group_id="O7">
            <title>475DC High Fat OMP</title>
            <description>Participants received DNX 50 mg HBr hemihydrate 475 DC formulation and OMP along with high fat meal</description>
          </group>
        </group_list>
        <measure>
          <title>Lag Time Before Observable Concentration (Tlag) of Danirixin for Part 2</title>
          <description>Blood samples were collected at the indicated time points after administration of study treatment to investigate the PK profile of Danirixin. PK parameters were calculated by standard non-compartmental analysis using WinNonlin based on actual sampling times.</description>
          <population>PK population. Only those participants with data available at specified time points were analyzed</population>
          <units>Hours</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="11"/>
                <count group_id="O6" value="11"/>
                <count group_id="O7" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.000" spread="0.0000"/>
                    <measurement group_id="O2" value="0.283" spread="0.3554"/>
                    <measurement group_id="O3" value="0.641" spread="0.4405"/>
                    <measurement group_id="O4" value="0.386" spread="0.4922"/>
                    <measurement group_id="O5" value="0.000" spread="0.0000"/>
                    <measurement group_id="O6" value="0.423" spread="0.3097"/>
                    <measurement group_id="O7" value="0.370" spread="0.6461"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Any Adverse Event (AE) and Serious Adverse Events in Part 2</title>
        <description>AE is any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. An SAE is any untoward medical occurrence that, at any dose results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect or is medically significant.</description>
        <time_frame>Up to 52 days in Part 2</time_frame>
        <population>mITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>475DC-Fasted</title>
            <description>Participants received a single dose of DNX 50 mg HBr hemihydrate 475 DC tablet formulation in fasted state</description>
          </group>
          <group group_id="O2">
            <title>475DC-Normal Meal</title>
            <description>Participants received DNX 50 mg HBr hemihydrate 475 DC formulation along with normal meal</description>
          </group>
          <group group_id="O3">
            <title>475DC-High Fat</title>
            <description>Participants received DNX 50 mg HBr hemihydrate 475 DC formulation along with high fat meal</description>
          </group>
          <group group_id="O4">
            <title>475DC-MONO High Fat</title>
            <description>Participants received DNX 50 mg HBr monohydrate 475 DC with 5 percent HPMC formulation along with high fat meal</description>
          </group>
          <group group_id="O5">
            <title>475DC Fasted OMP</title>
            <description>Participants received DNX 50 mg HBr hemihydrate 475 DC formulation and OMP under fasted condition</description>
          </group>
          <group group_id="O6">
            <title>475DC Normal Meal OMP</title>
            <description>Participants received DNX 50 mg HBr hemihydrate 475 DC formulation and OMP along with normal meal</description>
          </group>
          <group group_id="O7">
            <title>475DC High Fat OMP</title>
            <description>Participants received DNX 50 mg HBr hemihydrate 475 DC formulation and OMP along with high fat meal</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Any Adverse Event (AE) and Serious Adverse Events in Part 2</title>
          <description>AE is any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. An SAE is any untoward medical occurrence that, at any dose results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect or is medically significant.</description>
          <population>mITT Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="11"/>
                <count group_id="O6" value="11"/>
                <count group_id="O7" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any SAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Vital Signs of Potential Clinical Concern in Part 2</title>
        <description>Vital signs included systolic and diastolic blood pressure, temperature, respiratory rate and pulse rate were measured with participants in semi-supine position after 5 minutes rest.</description>
        <time_frame>Up to 52 days in Part 2</time_frame>
        <population>mITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>475DC-Fasted</title>
            <description>Participants received a single dose of DNX 50 mg HBr hemihydrate 475 DC tablet formulation in fasted state</description>
          </group>
          <group group_id="O2">
            <title>475DC-Normal Meal</title>
            <description>Participants received DNX 50 mg HBr hemihydrate 475 DC formulation along with normal meal</description>
          </group>
          <group group_id="O3">
            <title>475DC-High Fat</title>
            <description>Participants received DNX 50 mg HBr hemihydrate 475 DC formulation along with high fat meal</description>
          </group>
          <group group_id="O4">
            <title>475DC-MONO High Fat</title>
            <description>Participants received DNX 50 mg HBr monohydrate 475 DC with 5 percent HPMC formulation along with high fat meal</description>
          </group>
          <group group_id="O5">
            <title>475DC Fasted OMP</title>
            <description>Participants received DNX 50 mg HBr hemihydrate 475 DC formulation and OMP under fasted condition</description>
          </group>
          <group group_id="O6">
            <title>475DC Normal Meal OMP</title>
            <description>Participants received DNX 50 mg HBr hemihydrate 475 DC formulation and OMP along with normal meal</description>
          </group>
          <group group_id="O7">
            <title>475DC High Fat OMP</title>
            <description>Participants received DNX 50 mg HBr hemihydrate 475 DC formulation and OMP along with high fat meal</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Vital Signs of Potential Clinical Concern in Part 2</title>
          <description>Vital signs included systolic and diastolic blood pressure, temperature, respiratory rate and pulse rate were measured with participants in semi-supine position after 5 minutes rest.</description>
          <population>mITT Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="11"/>
                <count group_id="O6" value="11"/>
                <count group_id="O7" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="4"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With 12-lead Electrocardiogram (ECG) Values of Potential Clinical Concern in Part 2</title>
        <description>Single 12-lead ECGs were obtained using an ECG machine that automatically calculated the heart rate and measured PR, QRS, and QT intervals, and QT interval corrected by Fridericia's formula (QTcF). Number of participants with 12-lead ECG values of potential clinical concern in Part 2 are presented.</description>
        <time_frame>Up to 52 days in Part 2</time_frame>
        <population>mITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>475DC-Fasted</title>
            <description>Participants received a single dose of DNX 50 mg HBr hemihydrate 475 DC tablet formulation in fasted state</description>
          </group>
          <group group_id="O2">
            <title>475DC-Normal Meal</title>
            <description>Participants received DNX 50 mg HBr hemihydrate 475 DC formulation along with normal meal</description>
          </group>
          <group group_id="O3">
            <title>475DC-High Fat</title>
            <description>Participants received DNX 50 mg HBr hemihydrate 475 DC formulation along with high fat meal</description>
          </group>
          <group group_id="O4">
            <title>475DC-MONO High Fat</title>
            <description>Participants received DNX 50 mg HBr monohydrate 475 DC with 5 percent HPMC formulation along with high fat meal</description>
          </group>
          <group group_id="O5">
            <title>475DC Fasted OMP</title>
            <description>Participants received DNX 50 mg HBr hemihydrate 475 DC formulation and OMP under fasted condition</description>
          </group>
          <group group_id="O6">
            <title>475DC Normal Meal OMP</title>
            <description>Participants received DNX 50 mg HBr hemihydrate 475 DC formulation and OMP along with normal meal</description>
          </group>
          <group group_id="O7">
            <title>475DC High Fat OMP</title>
            <description>Participants received DNX 50 mg HBr hemihydrate 475 DC formulation and OMP along with high fat meal</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With 12-lead Electrocardiogram (ECG) Values of Potential Clinical Concern in Part 2</title>
          <description>Single 12-lead ECGs were obtained using an ECG machine that automatically calculated the heart rate and measured PR, QRS, and QT intervals, and QT interval corrected by Fridericia's formula (QTcF). Number of participants with 12-lead ECG values of potential clinical concern in Part 2 are presented.</description>
          <population>mITT Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="11"/>
                <count group_id="O6" value="11"/>
                <count group_id="O7" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Laboratory Values of Potential Clinical Concern in Part 2</title>
        <description>Hematology parameters included platelet count, RBC Count, hemoglobin, hematocrit, MCV, MCH, %Reticulocytes, neutrophils, lymphocytes, monocytes, eosinophils, basophils. Clinical chemistry parameters included potassium aspartate, Aminotransferase(AST)/Serum Glutamic-Oxaloacetic Transaminase (SGOT), total and direct, bilirubin, creatinine sodium alanine, Aminotransferase, (ALT)/ Serum Glutamic-Pyruvic, Transaminase (SGPT), total protein, fasting glucose, calcium, alkaline phosphatase and albumin. Urinalysis included specific gravity, potential of hydrogen (pH), glucose, protein, blood and ketones by dipstick and microscopic examination of urine.</description>
        <time_frame>Up to 52 days in Part 2</time_frame>
        <population>mITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>475DC-Fasted</title>
            <description>Participants received a single dose of DNX 50 mg HBr hemihydrate 475 DC tablet formulation in fasted state</description>
          </group>
          <group group_id="O2">
            <title>475DC-Normal Meal</title>
            <description>Participants received DNX 50 mg HBr hemihydrate 475 DC formulation along with normal meal</description>
          </group>
          <group group_id="O3">
            <title>475DC-High Fat</title>
            <description>Participants received DNX 50 mg HBr hemihydrate 475 DC formulation along with high fat meal</description>
          </group>
          <group group_id="O4">
            <title>475DC-MONO High Fat</title>
            <description>Participants received DNX 50 mg HBr monohydrate 475 DC with 5 percent HPMC formulation along with high fat meal</description>
          </group>
          <group group_id="O5">
            <title>475DC Fasted OMP</title>
            <description>Participants received DNX 50 mg HBr hemihydrate 475 DC formulation and OMP under fasted condition</description>
          </group>
          <group group_id="O6">
            <title>475DC Normal Meal OMP</title>
            <description>Participants received DNX 50 mg HBr hemihydrate 475 DC formulation and OMP along with normal meal</description>
          </group>
          <group group_id="O7">
            <title>475DC High Fat OMP</title>
            <description>Participants received DNX 50 mg HBr hemihydrate 475 DC formulation and OMP along with high fat meal</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Laboratory Values of Potential Clinical Concern in Part 2</title>
          <description>Hematology parameters included platelet count, RBC Count, hemoglobin, hematocrit, MCV, MCH, %Reticulocytes, neutrophils, lymphocytes, monocytes, eosinophils, basophils. Clinical chemistry parameters included potassium aspartate, Aminotransferase(AST)/Serum Glutamic-Oxaloacetic Transaminase (SGOT), total and direct, bilirubin, creatinine sodium alanine, Aminotransferase, (ALT)/ Serum Glutamic-Pyruvic, Transaminase (SGPT), total protein, fasting glucose, calcium, alkaline phosphatase and albumin. Urinalysis included specific gravity, potential of hydrogen (pH), glucose, protein, blood and ketones by dipstick and microscopic examination of urine.</description>
          <population>mITT Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="11"/>
                <count group_id="O6" value="11"/>
                <count group_id="O7" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>On-Treatment serious adverse events (SAEs) and non-serious AEs (nSAEs) were collected from start of study treatment until 81 days</time_frame>
      <desc>On-Treatment SAEs and nSAEs were reported for mITT Population.</desc>
      <group_list>
        <group group_id="E1">
          <title>600RC High Fat</title>
          <description>Participants received a single oral dose of DNX 50 mg HBr hemihydrate 600 RC tablet formulation along with a high fat meal</description>
        </group>
        <group group_id="E2">
          <title>475DC High Fat</title>
          <description>Participants received a single oral dose of DNX 50 mg HBr hemihydrate 475 DC tablet formulation along with high fat meal</description>
        </group>
        <group group_id="E3">
          <title>600DC High Fat</title>
          <description>Participants received a single oral dose of DNX 50 mg HBr hemihydrate 600 DC tablet formulation along with high fat meal</description>
        </group>
        <group group_id="E4">
          <title>600DC 5%HPMC High Fat</title>
          <description>Participants received a single oral dose of DNX 50 mg HBr hemihydrate 600 DC tablet with 5 percent HPMC formulation along with high fat meal</description>
        </group>
        <group group_id="E5">
          <title>600RC Fasted</title>
          <description>Participants received a single oral dose of DNX 50 mg HBr hemihydrate 600 RC tablet formulation under fasted condition</description>
        </group>
        <group group_id="E6">
          <title>475DC Fasted</title>
          <description>Participants received a single oral dose of DNX 50 mg HBr hemihydrate 475 DC tablet formulation under fasted condition</description>
        </group>
        <group group_id="E7">
          <title>600DC Fasted</title>
          <description>Participants received a single oral dose of DNX 50 mg HBr hemihydrate 600 DC tablet formulation under fasted condition</description>
        </group>
        <group group_id="E8">
          <title>600DC 5%HPMC Fasted</title>
          <description>Participants received a single oral dose of DNX 50 mg HBr hemihydrate 600 DC tablet with 5 percent HPMC formulation under fasted condition</description>
        </group>
        <group group_id="E9">
          <title>475DC-Fasted</title>
          <description>Participants received a single dose of DNX 50 mg HBr hemihydrate 475 DC tablet formulation in fasted state</description>
        </group>
        <group group_id="E10">
          <title>475DC-Normal Meal</title>
          <description>Participants received DNX 50 mg HBr hemihydrate 475 DC formulation along with normal meal</description>
        </group>
        <group group_id="E11">
          <title>475DC-High Fat</title>
          <description>Participants received DNX 50 mg HBr hemihydrate 475 DC formulation along with high fat meal</description>
        </group>
        <group group_id="E12">
          <title>475DC-MONO High Fat</title>
          <description>Participants received DNX 50 mg HBr monohydrate 475 DC with 5 percent HPMC formulation along with high fat meal</description>
        </group>
        <group group_id="E13">
          <title>475DC-Fasted OMP</title>
          <description>Participants received DNX 50 mg HBr hemihydrate 475 DC formulation and OMP under fasted condition</description>
        </group>
        <group group_id="E14">
          <title>475DC-Normal Meal OMP</title>
          <description>Participants received DNX 50 mg HBr hemihydrate 475 DC formulation and OMP along with normal meal</description>
        </group>
        <group group_id="E15">
          <title>475DC-High Fat OMP</title>
          <description>Participants received DNX 50 mg HBr hemihydrate 475 DC formulation and OMP along with high fat meal</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 21.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E15" subjects_affected="3" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E15" events="2" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Abnormal faeces</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E15" events="2" subjects_affected="2" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Vessel puncture site haematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Bursitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis contact</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

